Prostamax (KEDP): Khavinson Prostate Bioregulator Guide#

Prostamax is a synthetic tetrapeptide bioregulator with the sequence Lys-Glu-Asp-Pro (KEDP), developed by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology and proposed to act as a prostate-tissue-selective gene regulator (Khavinson VKh, Lezhava TA, Monaselidze JR, et al. Bulletin of Experimental Biology and Medicine 2004; PMID 15612551)¹. It is commonly mis-spelled "Prostoma" in user searches. Last verified June 4, 2026.

What is Prostamax?#

Prostamax is a synthetic tetrapeptide composed of four amino acids -- lysine, glutamic acid, aspartic acid, and proline (Lys-Glu-Asp-Pro), abbreviated KEDP. It belongs to the Khavinson family of "short-peptide bioregulators," a class of 2-4 amino-acid peptides proposed by Professor Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology to function as tissue-specific gene regulators. In the Khavinson framework, each organ has its own short-peptide "bioregulator": Epitalon (AEDG) for the pineal gland, Pinealon (EDR) for neuronal tissue, Vilon (KE) and Thymalin for the thymus and immune system, and Prostamax (KEDP) for the prostate.

The single PubMed-indexed canonical citation for Prostamax is Khavinson VKh, Lezhava TA, Monaselidze JR, et al., Bulletin of Experimental Biology and Medicine 2004 (PMID 15612551), which reports that Prostamax incubation reactivates constitutive heterochromatin and rRNA-gene transcription in peripheral-blood lymphocytes of donors aged 60-79 years¹. Within the Khavinson interpretation, this is offered as evidence that KEDP can "switch on" age-suppressed gene-expression states; mainstream molecular biology has not independently replicated the finding, and the proposed direct peptide-DNA binding mechanism remains controversial.

Prostamax is not an FDA-approved drug, not a prescription product in any Western jurisdiction, and not the same compound as the Khavinson pineal peptide Epitalon. Most non-PubMed Prostamax reports appear in Russian-language journals and as conference abstracts from the Khavinson program itself; the wider gerontology and urology literature has not adopted KEDP as a recognised intervention for benign prostatic hyperplasia (BPH) or prostate aging.

Mechanism of Action#

Proposed Tissue-Selective Bioregulation#

Within the Khavinson bioregulator theory, Prostamax is proposed to act as a prostate-tissue-selective gene regulator. The mechanism most often cited is direct peptide-DNA interaction at promoter regions of prostate-relevant genes, with the four-residue KEDP sequence proposed to recognise specific DNA motifs and modulate chromatin state. The same group has proposed analogous mechanisms for Epitalon (hTERT promoter), Pinealon (neural-gene promoters), and Vilon (thymic-gene promoters).

The PubMed-indexed Prostamax study (Khavinson 2004; PMID 15612551) reports two readouts that the authors interpret as evidence of gene-expression "rejuvenation"¹:

• Heterochromatin decondensation in lymphocytes from older donors -- interpreted as a return to a younger gene-expression state
• Increased rRNA-gene transcription -- interpreted as restoration of age-suppressed transcriptional activity

The study used peripheral-blood lymphocytes rather than prostate tissue, so direct prostate-selective activity has not been demonstrated in that report.

Mechanistic Plausibility Concerns#

The proposed mechanism -- a free four-amino-acid peptide (488 Da) reaching cell nuclei and binding DNA with sequence specificity -- faces the same theoretical challenges raised for other Khavinson short peptides. Classical sequence-specific DNA-binding proteins (zinc fingers, helix-turn-helix, leucine zippers) require complex tertiary structure; a tetrapeptide lacks the structural complexity normally required for selective DNA recognition. Independent biophysical confirmation of KEDP-DNA binding has not been published by groups outside the Khavinson program.

Alternative mechanisms -- indirect effects via cell-surface receptors, signalling cascades, or non-specific antioxidant activity common to short peptides -- have not been rigorously investigated for Prostamax.

Therapeutic Claims and Evidence Base#

Prostate-Aging and BPH Models#

Russian-language reports from the Khavinson group describe Prostamax administration to aged-rat models with histological readouts (epithelial-stromal ratio, alveolar diameter) interpreted as restoration toward younger phenotypes, and small clinical observations in Russian bioregulation clinics for symptomatic BPH. These reports are not PubMed-indexed, do not appear in randomised trial registries, and have not been independently replicated.

What Prostamax Is Not#

• Not FDA, EMA, MHRA, or Health Canada-approved for BPH, prostate cancer, or any other indication
• Not the same as Epitalon -- different sequence (KEDP vs AEDG), different proposed target tissue (prostate vs pineal)
• Not a 5-alpha reductase inhibitor -- it does not share a mechanism with finasteride or dutasteride
• Not the same as commercial "Prostoma" supplements -- some are unrelated multi-ingredient products marketed for prostate health under similar brand names

Evidence Quality#

Using standard evidence-pyramid grading, Prostamax sits at the lowest tier: a single PubMed-indexed in-vitro study (PMID 15612551), additional Russian-language reports concentrated in a single research program, no registered randomised trials, no independent replication. By the GRADE framework this maps to very-low quality evidence for any clinical claim.

Important Considerations#

• Prostamax (KEDP) is a research compound, not an approved medicine in any Western regulatory jurisdiction
• The single PubMed-indexed citation (PMID 15612551) is an in-vitro lymphocyte study, not a prostate clinical trial
• The Khavinson bioregulator framework remains controversial; direct peptide-DNA gene regulation is not a mainstream molecular-biology mechanism
• Material sold online as "Prostamax" or "Prostoma" is not subject to pharmaceutical manufacturing standards; purity and identity are not guaranteed
• Men with suspected BPH or other prostate concerns should consult a clinician about evidence-based interventions (alpha blockers, 5-alpha reductase inhibitors) rather than self-administering Prostamax

Key Research Findings#

Prostamax reactivates heterochromatin and rRNA-gene transcription in lymphocytes of older donors, published in Bulletin of Experimental Biology and Medicine (Khavinson VKh, Lezhava TA, Monaselidze JR, et al., 2004; PMID 15612551):

• Single canonical PubMed-indexed Prostamax study
• In-vitro lymphocyte model, not prostate tissue
• Interpreted by authors as evidence of age-related gene-expression reactivation
• No independent replication by labs outside the Khavinson program

References#

Related Reading#

• Prostamax research studies and evidence
• Prostamax dosing protocols
• Prostamax side effects profile
• Epitalon research guide
• Pinealon research guide
• Vesugen (KED) research guide
• Vilon research guide
• Thymalin research guide

Footnotes#

1. Khavinson VKh, Lezhava TA, Monaselidze JR, et al. Peptides reactivate heterochromatin and rRNA gene transcription in lymphocyte cultures of elderly donors. Bulletin of Experimental Biology and Medicine. 2004. PMID: 15612551. ↩ ↩² ↩³